Autoimmune inflammatory disorders

Our ambition

Our ambition is to develop novel protein and peptide therapies that will significantly improve the lives of people with autoimmune diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease (Crohn's Disease and ulcerative colitis). The goal is to develop compounds that are clearly differentiated from current therapies.

Our partnering focus

Novo Nordisk is committed to building a presence in the area of AID.

We welcome protein and peptide opportunities from research to clinical stage, including possibly novel protein and peptide formats such e.g. bispecific molecules. We focus on mechanisms of action that interfere with the immune system, but also targeting non-immune cells/mechanisms that can impact disease process and thereby benefit patients.

Read more about Biopharmaceuticals Research Unit

Contact us

For further information, please contact:

Anand Gautam 

Brendan Classon 

  •  

Download partnering for innovation brochure

  •  
  •  

Where to meet us

We are attending events all over the world to meet with new potential partners.

Event calendar

  •  
  •  

R&D pipeline

Read more about our inflammation pipeline.

  •